Cytogenetic Risk Groups
| Risk Group . | Abnormality . | Comment . |
|---|---|---|
| Favorable | t(8;21) t(15;17) inv(16) | Whether alone or in conjunction with other abnormalities. |
| Intermediate | Normal +8 +21 +22 del(7q) del(9q) Abnormal 11q23 All other structural/numerical abnormalities | ie, Cytogenetic abnormalities not classified as favorable or adverse. Lack of additional favorable or adverse cytogenetic changes. |
| Adverse | −5 −7 del(5q) Abnormal 3qComplex | Whether alone or in conjunction with intermediate-risk or other adverse-risk abnormalities. |
| Risk Group . | Abnormality . | Comment . |
|---|---|---|
| Favorable | t(8;21) t(15;17) inv(16) | Whether alone or in conjunction with other abnormalities. |
| Intermediate | Normal +8 +21 +22 del(7q) del(9q) Abnormal 11q23 All other structural/numerical abnormalities | ie, Cytogenetic abnormalities not classified as favorable or adverse. Lack of additional favorable or adverse cytogenetic changes. |
| Adverse | −5 −7 del(5q) Abnormal 3qComplex | Whether alone or in conjunction with intermediate-risk or other adverse-risk abnormalities. |
Hierarchical prognostic classification, derived taking into consideration the influence of additional cytogenetic abnormalities on outcome, and used for directing treatment approach in the current MRC AML 12 trial.